Publication of potentially prac- tice-changing new study results relevant to an existing or new drug, device, or management strategy prompts evaluation by the Task Force, in consultation with the relevant guideline writing committee, to determine whether a focused update should be commissioned. For additional information and policies on guideline de- velopment, we encourage readers to consult the ACC/ AHA guideline methodology manualP-4 and other meth- Selection of Writing Committee Members The Task Force strives to ensure that the guideline writing committee both contains requisite expertise and is representative of the broader medical commu- nity by selecting experts from a broad array of back- grounds, representing different geographic regions, sexes, races, ethnicities, intellectual perspectives/bi- ases, and scopes of clinical practice, and by inviting organizations and professional societies with related interests and expertise to participate as partners or collaborators. Relationships With Industry and Other Entities The ACC and AHA have rigorous policies and meth- ods to ensure that documents are developed without bias or improper influence. The complete policy on relationships with industry and other entities (RWI) can be found online. Appendix 1 of the guideline lists writing committee members relevant RWI; for the purposes of full transparency, their comprehensive disclosure information is available online. Compre- hensive disclosure information for the Task Force is also available online. Evidence Review and Evidence Review Committees In developing recommendations, the writing commit- tee uses evidence-based methodologies that are based on all available data.P-4 P-6 Literature searches focus on randomized controlled trials (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion. Only key references are cited. 